|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM032806833 |
| 003 |
DE-627 |
| 005 |
20250126160336.0 |
| 007 |
tu |
| 008 |
231221s1986 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed25n0110.xml
|
| 035 |
|
|
|a (DE-627)NLM032806833
|
| 035 |
|
|
|a (NLM)3299393
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Jaffé, G V
|e verfasserin
|4 aut
|
| 245 |
1 |
2 |
|a A clinical trial of hydrocortisone/potassium hydroxyquinoline sulphate ('Quinocort') in the treatment of infected eczema and impetigo in general practice
|
| 264 |
|
1 |
|c 1986
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 29.07.1987
|
| 500 |
|
|
|a Date Revised 21.11.2013
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a A double-blind, multi-centre study was carried out in general practice in 76 patients with infected eczema and 43 with impetigo to assess the effectiveness and acceptability of treatment with 1% hydrocortisone plus 0.5% potassium hydroxyquinoline sulphate cream compared with that of 1% hydrocortisone plus 2% miconazole nitrate cream. Patients were allocated at random to receive treatment with one or other preparation, applied twice daily, over a period of 2 weeks. Assessments were made of total symptom severity scores on entry and at the end of each week, as also were bacteriological investigations. The results showed that both combinations produced marked clinical and bacteriological improvement or cure in approximately 90% of patients with infected eczema and the success rate was similar with each preparation. In the case of patients with impetigo, hydrocortisone/potassium hydroxyquinoline sulphate proved significantly more effective than the other combination, the success rates being 92% and 74%, respectively. Patient assessment of the two topical preparations in terms of greasiness, odour and staining showed that, whilst both were considered acceptable by most, there was a trend in favour of the hydrocortisone/potassium hydroxyquinoline sulphate cream. No systemic or local side-effects were reported
|
| 650 |
|
4 |
|a Clinical Trial
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Randomized Controlled Trial
|
| 650 |
|
7 |
|a Drug Combinations
|2 NLM
|
| 650 |
|
7 |
|a Hydroxyquinolines
|2 NLM
|
| 650 |
|
7 |
|a Miconazole
|2 NLM
|
| 650 |
|
7 |
|a 7NNO0D7S5M
|2 NLM
|
| 650 |
|
7 |
|a Hydrocortisone
|2 NLM
|
| 650 |
|
7 |
|a WI4X0X7BPJ
|2 NLM
|
| 700 |
1 |
|
|a Grimshaw, J J
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Pharmatherapeutica
|d 1985
|g 4(1986), 10 vom: 02., Seite 628-36
|w (DE-627)NLM023961570
|x 0308-051X
|7 nnns
|
| 773 |
1 |
8 |
|g volume:4
|g year:1986
|g number:10
|g day:02
|g pages:628-36
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_31
|
| 912 |
|
|
|a GBV_ILN_39
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_72
|
| 912 |
|
|
|a GBV_ILN_120
|
| 912 |
|
|
|a GBV_ILN_121
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 4
|j 1986
|e 10
|b 02
|h 628-36
|